Jennifer Cannizzaro
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,251 and has fallen 92.4% since, to $95 in 2023.
Across 125 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$445
- AbbVie$314
- Otsuka America Pharmaceutical, Inc.$296
- Alkermes, Inc.$236
- Neurocrine Biosciences, Inc.$210
- Neuronetics, Inc.$188
- plus $833 from 12 others
What the payments were for
- Food & beverage$2,45897%
- Education$643%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $445 |
| AbbVie | 19 | $314 |
| Otsuka America Pharmaceutical, Inc. | 17 | $296 |
| Alkermes, Inc. | 13 | $236 |
| Neurocrine Biosciences, Inc. | 9 | $210 |
| Neuronetics, Inc. | 7 | $188 |
| Vanda Pharmaceuticals Inc. | 6 | $172 |
| Lundbeck LLC | 7 | $137 |
| Eisai Inc. | 5 | $72 |
| Alfasigma USA, Inc. | 4 | $65 |
| Bausch Health US, LLC | 3 | $64 |
| Sunovion Pharmaceuticals Inc. | 3 | $62 |
| Johnson & Johnson | 3 | $59 |
| Orexo US, Inc. | 3 | $56 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Supernus Pharmaceuticals, Inc. | 3 | $38 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
How this compares
$2,522 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 68 | $6,501 |
| Tizanidine Hcl | 11 | $45 |
Paid to pharmacies, not to this prescriber.
Other family in Tampa
- Lewis HarringtonTampa$954K
- Marie Labadie-DegennaroTampa$66K
- Polly BittleTampa$63K
- Katharine WilliamsTampa$47K
- Candace DeberryTampa$46K
- Bailey BlankenshipTampa$42K
- Rasheeta ChandlerTampa$37K
- Rosaly TorresTampa$28K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.